Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

Stopped Investigators are no longer considering FMT product development for C. difficile.

Conditions

• Recurrent C. Difficile Infection

Interventions

• BIOLOGICAL: Low fecal microbiota dose
• BIOLOGICAL: Mid fecal microbiota dose
• BIOLOGICAL: High fecal microbiota dose

Sponsor

The University of Texas Health Science Center, Houston